For adult and adolescent patients ≥12 years of age
Freedom from daily dosing
Ready-to-use self-injection that allows control of injection speed1
≤1
MINUTE TO SELF-INJECT
for most people in the clinical studies1*
2
EVERY-2-WEEKS
DOSING1
3
CHOICES FOR INJECTION SITE
abdomen, thigh, or upper arm1
The TAKHZYRO prefilled syringe is a smaller gauge than other subcutaneous injections, such as those used for1,3,4
- Vaccinations (22-25 gauge, 1-1.5 inches)3
- FIRAZYR (icatibant [25 gauge, 0.625 inch])3,4
- TAKHZYRO has a half-life of ~14 days; therefore, it takes ~10 weeks (ie, 6 doses) to reach steady state and ~2 weeks until 50% of TAKHZYRO is eliminated from the body1,2
- The recommended starting dose for patients 12 years of age and older is 300 mg every 2 weeks. TAKHZYRO 300 mg every 4 weeks is also effective and may be considered if the patient is well-controlled (eg, attack-free) for more than 6 months1
All data presented are for TAKHZYRO 300 mg every 2 weeks unless otherwise indicated.
*In clinical studies, the majority of patients self-administered TAKHZYRO within 10 to 60 seconds. These injection times are based on vial administration.1
For pediatric patients 2 to <12 years of age
A lower dose for younger patients
Age-based dosing interval of every 2 or 4 weeks.1
Remind your patients and their caregivers to always have acute treatment on hand and periodically check the date to ensure it hasn't expired.
AGES
NUMBER OF DOSES PER MONTH
2 TO <6 YEARS
1 150 mg/1 mL
SUBCUTANEOUS INJECTIONS
(1 INJECTION EVERY 4 WEEKS)1
6 TO <12 YEARS
2 150 mg/1 mL
SUBCUTANEOUS INJECTIONS
(1 INJECTION EVERY 2 WEEKS)1
A dosing interval of 150 mg every 4 weeks may be considered if the patient is well-controlled (eg, attack free) for more than 6 months.1
One month is defined as 28 days.
The TAKHZYRO
prefilled syringe
TAKHZYRO is available in a single-dose, ready-to-go, prefilled syringe!1 Compared to a vial, the prefilled syringe offers:
- FEWER STEPS
- FEWER SUPPLIES
- LESS WASTE